TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
TEVA PHARMACEUTICAL INDUSTRIES LTD
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$41.31−0.19 (-0.46%)
Close on Oct 19, 2026
- Market cap
- $48.13B
- P/E (TTM)
- 68.9
- Dividend yield
- –
TEVA PHARMACEUTICAL INDUSTRIES LTD revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States [Member] | $1.70B | $1.53B | $2.64B | $2.48B | $1.79B | $1.54B | $1.97B | $2.23B | $2.11B | $1.73B | $2.27B | $1.90B | 41.1% | -4.7% |
| Europe [Member] | $1.26B | $1.34B | $1.31B | $1.24B | $1.30B | $1.19B | $1.35B | $1.27B | $1.21B | $1.27B | $1.34B | $1.15B | 30.5% | -2.7% |
| Other Activities [Member] | $627.00M | $584.00M | $226.00M | $205.00M | $597.00M | $579.00M | $241.00M | $229.00M | $249.00M | $225.00M | $245.00M | $217.00M | 15.1% | +5.0% |
| International Markets [Member] | $550.00M | $524.00M | $528.00M | $557.00M | $495.00M | $582.00M | $661.00M | $613.00M | $593.00M | $597.00M | $601.00M | $591.00M | 13.3% | +11.1% |
| North America [Member] | – | – | – | – | – | – | – | – | – | – | $2.37B | $2.00B | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Segment [Member] | $391.00M | $972.00M | $1.56B | $1.33B | $1.14B | $944.00M | $1.15B | $1.23B | $1.04B | $890.00M | $1.54B | $1.03B | -65.6% |
| Europe [Member] | $367.00M | $401.00M | $307.00M | $303.00M | $364.00M | $329.00M | $438.00M | $373.00M | $342.00M | $423.00M | $461.00M | $338.00M | +0.8% |
| International Markets [Member] | $99.00M | $65.00M | $70.00M | $95.00M | $74.00M | $97.00M | $141.00M | $109.00M | $73.00M | $117.00M | $109.00M | $117.00M | +33.8% |
| Other Segments [Member] | -$16.00M | -$16.00M | -$26.00M | -$40.00M | -$3.00M | $2.00M | $19.00M | -$16.00M | $12.00M | $2.00M | $2.00M | -$5.00M | +433.3% |
| United States [Member] | -$76.00M | $507.00M | $1.18B | $937.00M | $699.00M | $518.00M | $569.00M | $748.00M | $629.00M | $350.00M | $973.00M | $571.00M | -110.9% |
| Segments and Other Activities [Member] | – | – | – | – | – | – | – | $1.21B | $1.06B | $892.00M | $1.55B | $1.02B | – |
| North America [Member] | – | – | – | – | – | – | – | – | – | – | $967.00M | $577.00M | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sale of Goods [Member] | $3.60B | $3.39B | $3.67B | $3.91B | $3.64B | $3.40B | $3.42B | $3.73B | $3.64B | $3.27B | $3.26B | $3.30B | 87.0% | -0.9% |
| Distribution [Member] | $433.00M | $396.00M | $384.00M | $406.00M | $377.00M | $384.00M | $413.00M | $390.00M | $382.00M | $391.00M | $403.00M | $377.00M | 10.5% | +14.9% |
| Other [Member] | $70.00M | $157.00M | $109.00M | $121.00M | $117.00M | $76.00M | $346.00M | $172.00M | $106.00M | $121.00M | $252.00M | $117.00M | 1.7% | -40.2% |
| Licensing Arrangements [Member] | $37.00M | $39.00M | $550.00M | $46.00M | $46.00M | $36.00M | $52.00M | $45.00M | $36.00M | $40.00M | $547.00M | $53.00M | 0.9% | -19.6% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.70B | $1.53B | $2.64B | $2.48B | $1.79B | $1.54B | $1.97B | $2.23B | $2.11B | $1.73B | $2.27B | $1.90B | 41.1% | -4.7% |
| Europe [Member] | $1.26B | $1.34B | $1.31B | $1.24B | $1.30B | $1.19B | $1.35B | $1.27B | $1.21B | $1.27B | $1.34B | $1.15B | 30.5% | -2.7% |
| North America [Member] | – | – | – | – | – | – | – | – | – | – | $2.37B | $2.00B | – | – |
From the segment and revenue-disaggregation notes of Teva Pharmaceutical Industries's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.